Replies to post #4842 on Momenta Pharmaceuticals, Inc. (MNTA)

[go seek]

biosimilars reply by DD... #msg-65974383

[IB2011]

Doesn't this imply that Teva has an uphill fight to gain approval for T-Enox? Let's see, a perpetuity of $360 million from M-Enox, less taxes at 35%, equals $234 million. With a discount rate of 12.5%, the present value of M-Enox royalties is $1.872 billion. Then you add back the current cash and A/R, etc.